TABLE 3.
Regression analyses between Δplasma protein levels measured in normalized protein expression scale, expressed in AU, and ∆T score from the lumbar spine (A) and femoral neck (B).
| (A) Plasma protein | β | (95% CI) | p | Adjusted p a |
|---|---|---|---|---|
| ΔMelusin | 1.20 | (1.03; 1.40) | 0.028* | 0.809 |
| ΔOsteoprotegerin | 1.01 | (0.48; 2.14) | 0.974 | 0.993 |
| ΔCCN1 | 0.96 | (0.48; 1.94) | 0.912 | 0.993 |
| ΔWISP1 | 1.02 | (0.62; 1.68) | 0.935 | 0.993 |
| ΔCOL1A1 | 1.34 | (0.75; 2.39) | 0.337 | 0.993 |
| ΔITGB2 | 0.84 | (0.42; 1.69) | 0.624 | 0.993 |
| ΔITGAV | 0.53 | (0.15; 1.88) | 0.334 | 0.993 |
| ΔDecorin | 0.58 | (0.13; 2.61) | 0.485 | 0.993 |
| ΔMMP2 | 1.04 | (0.54; 2.02) | 0.908 | 0.993 |
| ΔStromelysin-1 | 0.97 | (0.67; 1.40) | 0.868 | 0.993 |
| ΔMatrilysin | 0.81 | (0.38; 1.72) | 0.589 | 0.993 |
| ΔOsteonectin | 3.25 | (0.55; 19.20) | 0.206 | 0.993 |
| ΔOsteopontin | 1.25 | (0.86; 1.81) | 0.259 | 0.993 |
| ΔTR-AP | 1.14 | (0.67; 1.94) | 0.641 | 0.993 |
| ΔMMP9 | 1.31 | (0.97; 1.77) | 0.089 | 0.993 |
| ΔITGB5 | 1.55 | (0.55; 4.35) | 0.417 | 0.993 |
| ΔSyndecan-1 | 1.23 | (0.84; 1.81) | 0.298 | 0.993 |
| ΔCadherin-5 | 0.34 | (0.09; 1.25) | 0.117 | 0.993 |
| ΔGlypican-1 | 0.84 | (0.31; 2.25) | 0.725 | 0.993 |
| ΔThrombospondin-2 | 0.77 | (0.29; 2.07) | 0.615 | 0.993 |
| ΔMMP12 | 1.02 | (0.65; 1.62) | 0.926 | 0.993 |
| ΔProlargin | 0.78 | (0.22; 2.79) | 0.706 | 0.993 |
| ΔPerlecan | 1.27 | (0.49; 3.25) | 0.628 | 0.993 |
| ΔGPNMB | 0.49 | (0.06; 3.97) | 0.512 | 0.993 |
| ΔhOSCAR | 0.88 | (0.19; 4.17) | 0.877 | 0.993 |
| ΔTIMP4 | 1.02 | (0.59; 1.77) | 0.934 | 0.993 |
| ΔFGF23 | 1.04 | (0.88; 1.22) | 0.669 | 0.993 |
| ΔMEPE | 1.00 | (0.42; 2.39) | 0.993 | 0.993 |
| ΔRANK | 1.47 | (0.86; 2.49) | 0.169 | 0.993 |
| (B) Plasma protein | ||||
| ΔTR-AP | 1.23 | (1.07; 1.42) | 0.007* | 0.189 |
| ΔITGB2 | 1.25 | (1.03; 1.52) | 0.032* | 0.435 |
| ΔStromelysin-1 | 0.90 | (0.81; 0.99) | 0.045* | 0.435 |
| ΔMMP2 | 0.83 | (0.69; 1.00) | 0.063 | 0.457 |
| ΔGPNMB | 0.60 | (0.33; 1.06) | 0.094 | 0.481 |
| ΔTIMP4 | 0.88 | (0.75; 1.03) | 0.116 | 0.481 |
| ΔFGF23 | 0.96 | (0.92; 1.01) | 0.106 | 0.481 |
| ΔOsteonectin | 1.47 | (0.88; 2.46) | 0.158 | 0.528 |
| ΔMelusin | 1.04 | (0.99; 1.09) | 0.164 | 0.528 |
| ΔProlargin | 0.77 | (0.53; 1.12) | 0.184 | 0.534 |
| ΔCCN1 | 1.14 | (0.93; 1.39) | 0.213 | 0.547 |
| ΔCOL1A1 | 0.90 | (0.76; 1.07) | 0.238 | 0.547 |
| ΔITGB5 | 1.20 | (0.89; 1.62) | 0.245 | 0.547 |
| ΔWISP1 | 0.92 | (0.80; 1.06) | 0.280 | 0.557 |
| ΔDecorin | 1.28 | (0.82; 2.01) | 0.288 | 0.557 |
| ΔITGAV | 0.83 | (0.57; 1.21) | 0.341 | 0.618 |
| ΔThrombospondin-2 | 0.88 | (0.65; 1.18) | 0.387 | 0.624 |
| ΔPerlecan | 0.88 | (0.66; 1.17) | 0.381 | 0.624 |
| ΔOsteopontin | 1.04 | (0.93; 1.17) | 0.471 | 0.719 |
| ΔMatrilysin | 0.94 | (0.75; 1.17) | 0.569 | 0.745 |
| ΔGlypican-1 | 0.92 | (0.69; 1.23) | 0.575 | 0.745 |
| ΔMMP12 | 1.04 | (0.91; 1.19) | 0.591 | 0.745 |
| ΔRANK | 1.05 | (0.89; 1.24) | 0.564 | 0.745 |
| ΔOsteoprotegerin | 0.95 | (0.75; 1.18) | 0.627 | 0.758 |
| ΔMEPE | 0.94 | (0.73; 1.22) | 0.658 | 0.763 |
| ΔSyndecan-1 | 0.98 | (0.87; 1.10) | 0.714 | 0.796 |
| ΔCadherin-5 | 0.95 | (0.63; 1.43) | 0.801 | 0.830 |
| ΔhOSCAR | 1.07 | (0.67; 1.71) | 0.791 | 0.830 |
| ΔMMP9 | 1.01 | (0.91; 1.11) | 0.910 | 0.910 |
Adjusted with Benjamini & Hochberg (false discovery rate) correction.
Δ, delta (post-HT—pre-HT values); AU, arbitrary units; CCN1, CCN family member 1; CI, confidence interval; COL1A1, collagen alpha-1(I) chain; FGF23, fibroblast growth factor 23; ITGAV, integrin alpha-V; ITGB2, integrin beta-2; ITGB5, integrin beta-5; MEPE, matrix extracellular phosphoglycoprotein; MMP, matrix metalloproteinase; TIMP4, metalloproteinase inhibitor 4; hOSCAR, osteoclast-associated immunoglobulin-like receptor; RANK, receptor activator of nuclear factor κ-B; TR-AP, tartrate-resistant acid phosphatase type 5; GPNMB, transmembrane glycoprotein NMB; WISP1, WNT1-inducible-signaling pathway protein 1. *Indicates statistical significance.